Xeris Pharmaceuticals | XERS - Interest Expense On Debt

Stock Price
7.85
Daily Change
-0.04 -0.51%
Monthly
42.99%
Yearly
212.75%
Q3 Forecast
7.78

Xeris Pharmaceuticals reported $7.36M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 334.69M
Cash and Equivalent USD 59.28M
Cost of Sales USD 11.9M
Current Assets USD 185.58M
Current Liabilities USD 95.17M
Debt USD 257.22M
EBIT USD 5.43M
EBITDA USD 8.59M
Employees 377
EPS Earnings Per Share USD -0.01
Equity Capital and Reserves USD -19.3M
Gross Profit on Sales USD 59.64M
Interest Expense on Debt USD 7.36M
Interest Income USD 948K
Loan Capital USD 218.63M
Market Capitalization USD 1.1B
Net Income USD -1.93M
Operating Expenses USD 67.06M
Operating Profit USD 4.48M
Ordinary Share Capital USD 161.22M
Pre-Tax Profit USD -1.93M
Sales Revenues USD 71.54M
Selling and Administration Expenses USD 44.39M
Stock USD 67.28M
Trade Creditors USD 9.46M
Trade Debtors USD 53.05M

Interest Expense On Debt Change Date
Celltrion KRW 17.04B 1.34B Mar/2025
Cspc Pharmaceutical 10.38M 934K Dec/2024
Dianthus Therapeutics 4.44M 263K Sep/2024
Divis Laboratories Ltd 30M 20M Jun/2025
Eli Lilly USD 249M 5.3M Jun/2025
Kangmei Pharma CNY 1.67M 1.45M Mar/2025
Knight Therapeutics CAD 1.91M 369K Sep/2024
Laboratorios Farma 699K 666.2K Jun/2025
Medical Developments International AUD 21K 23K Jun/2024
Neuren Pharmaceuticals 0 0 Jun/2024
Pacira USD 3.82M 110K Jun/2025
Perrigo 39.6M 600K Jun/2025
Qiagen NV USD 7.6M 311K Jun/2025
Sartorius 41.4M 51.4M Jun/2025
Sino Biopharmaceutical CNY 76.87M 114.23M Jun/2024
Supernus Pharmaceuticals USD 0 0 Dec/2024
Tilray USD 7.77M 2.08M Nov/2024
Zz Pientze Pharmaceu 46.05M 36.5M Jun/2025